Qvar is a controller and cannot relieve an acute asthma attack.
Use the prescribed rescue plan for acute symptoms and obtain urgent care if breathing is severe or rescue fails. Sudden wheezing immediately after Qvar requires stopping it and prompt bronchodilator/medical assessment. Use correct device technique and never independently stop or rapidly replace systemic steroids.
Warnings and precautionsIndications
Route-specific maintenance treatment.
Qvar asthma indication
Maintenance/prophylactic asthma treatment in adults and children ≥4 years. Not relief of acute bronchospasm and not primary treatment for status asthmaticus. This selected label does not establish COPD approval or guideline-preferred step therapy.
Qnasl allergic rhinitis
Nasal symptoms associated with seasonal/perennial allergic rhinitis in patients ≥4 years. It is an intranasal product, not an inhaled asthma rescue/controller substitute. No unverified nasal-polyp or other route indication.
Dosage and administration
Select strength and age regimen before device teaching.
Qvar Redihaler doses
| Age / prior therapy | Dose by oral inhalation |
|---|---|
| ≥12 years, not using ICS | Start 40–80 mcg twice daily, approximately 12 hours apart. |
| ≥12 years, switching ICS | Clinician-selected 40, 80, 160 or 320 mcg twice daily based on prior product/disease severity; maximum 320 mcg twice daily. No universal equivalent-dose conversion. |
| 4–11 years | Start 40 mcg twice daily; if inadequate after 2 weeks, may increase to 80 mcg twice daily. Maximum 80 mcg twice daily. |
| Response / titration | ≥12 years inadequate after 2 weeks may warrant increase/reassessment. Benefit may begin 24 hours but maximum often 3–4 weeks; follow clinician plan and titrate down to lowest effective dose. |
Qvar breath-actuated technique
No priming, no shaking, no spacer/holding chamber. Close cap to prepare each inhalation; upright mouthpiece down. Open only when ready; if open>2 minutes close then reopen. Breathe out away from device, seal lips and inhale deeply; hold breath 5–10 seconds, then exhale away. Close cap before repeating. After prescribed inhalations rinse mouth with water and spit; never wash device, wipe mouthpiece weekly with dry cloth. Not a press-and-breathe inhaler.
Qnasl nasal doses and technique
| Age / device | Once-daily intranasal dose |
|---|---|
| ≥12 years, 80 mcg actuator | 2 sprays each nostril once daily=320 mcg/day; maximum 4 total sprays/day. |
| 4–11 years, 40 mcg actuator | 1 spray each nostril once daily=80 mcg/day; maximum 2 total sprays/day. |
| Technique | No priming in currentPI and both current-served IFUs. Blow nose first, device upright, aim away from septum, close other nostril. Hold breath while pressing canister, continue holding 5 seconds then exhale through mouth; do not blow nose 15 minutes. Repeat prescribed sprays. Wipe dry; no water cleaning. |
Systemic steroid transition
Qvar does not supply systemic steroid replacement during stress. Withdrawal from systemic corticosteroids must be slow and clinician-supervised with lung function, symptoms/rescue use and adrenal monitoring; prolonged recovery can take months. Obtain a specific stress-dose/emergency plan rather than independently stopping oral steroids or copying an unreviewed taper.
Safety
Local infection, adrenal effects and technique errors need attention.
Warnings and precautions
- Qvar: mouth/pharyngeal Candida can occur; rinse/spit after dose, obtain treatment and supervised temporary interruption if needed. Worsening asthma or rescue failure requires immediate review; paradoxical wheeze after dose needs prompt rescue bronchodilator, stop Qvar and alternative therapy.
- Qnasl: nosebleeds, discomfort/ulcers, Candida or septal perforation possible; inspect mucosa periodically with months-long use, discontinue for erosion/ulceration. Avoid until recent nasal injury/surgery/ulcers heal.
- Both: serious hypersensitivity including angioedema/bronchospasm requires stopping and urgent care. Corticosteroids can worsen infection; review TB/untreated infections/ocular herpes and promptly report measles/chickenpox exposure when susceptible.
- Both: high doses/susceptibility can cause hypercorticism/adrenal suppression, including crisis during systemic-steroid withdrawal/stress. Clinician-directed slow reduction/transition, not abrupt self-discontinuation.
- Monitor pediatric growth, eye symptoms/glaucoma/cataract risks; Qvar long-term users with bone-risk factors require assessment/treatment under usual care.
Contraindications
Qvar: primary treatment of status asthmaticus/other acute asthma requiring intensive measures, or ingredient/beclomethasone hypersensitivity. Qnasl: ingredient/beclomethasone hypersensitivity. Nasal wound-healing/infection and systemic steroid-transfer warnings are important restrictions, not invented formal contraindications.
Boxed warning · status
Neither selected Qvar Redihaler nor Qnasl label has a boxed warning. Acute-asthma limitations and systemic/local corticosteroid risks remain clinically significant.
Adverse reactions and overdose
Qvar trials report oral thrush, upper-respiratory/nasopharyngeal symptoms, throat pain, cough/headache and other events; postmarketing behavioral/mood effects (primarily children) and eye disorders are reported. Qnasl commonly nasal discomfort/epistaxis/headache; pediatric fever/URI also reported. Excess chronic dosing can cause hypercorticism/adrenal suppression; Qnasl has no acute/chronic overdose data and Qvar supplies no dedicated overdose section. Seek professional assessment for excess dosing/serious symptoms; no home antidote or unsupervised abrupt taper.
Drug interactions
Selected device-specific interaction studies are absent.
Interaction evidence boundaries
Qvar 12.3 reports no in-vitro/in-vivo interaction studies; Qnasl 7 reports no interaction studies. This is not proof of interaction-free use. Qvar describes esterase activation, while Qnasl describes first-passCYP3A4 metabolism; no numerical strong-inhibitor dose adjustment or universal pathway claim invented.
Steroid and asthma-plan coordination
Review all steroid routes and prescribed rescue/controller medicines. Transition off systemic corticosteroids can cause adrenal insufficiency or unmask previously controlled allergies; do not use Qvar/Qnasl as an independent systemic-steroid replacement. Additional controller therapy or dosing changes require clinical asthma/rhinitis review.
Use in specific populations
Both selected products start at age 4 with separate doses.
Renal and hepatic considerations
Qvar renal/hepaticPK effects not evaluated; Qnasl formal special-populationPK studies absent. Neither supplies a numerical organ-adjustment/dialysis schedule. Review disease, total steroid exposure and clinical response rather than assume absence of systemic activity or copy another steroid’s table.
Children and older adults
Selected products establish use≥4 years; below 4 unestablished. Use age-specific product/dose, monitor growth routinely and lowest effective exposure. Elderly study numbers insufficient for firm age comparisons; select treatment cautiously with actual organ function/comorbidities and medicines, no invented reduced-age dose.
Pregnancy and lactation
No adequate controlled pregnancy studies; available observational human data do not establish presence/absence of fetal risk. Maintain asthma control because poorly controlled disease risks mother/fetus; adjust with clinician. Human milk/infant effects unknown for these products; consider breastfeeding benefit, maternal need and infant risk. No absolute pregnancy-safe claim, fertility guarantee or fixed milk-discard period.
Clinical pharmacology
Prodrug conversion yields active 17-monopropionate.
Mechanism
Corticosteroid anti-inflammatory actions affect inflammatory cells and mediators; precise asthma/rhinitis mechanisms are not fully known. Beclomethasone dipropionate is converted to active 17-BMP. In-vitro receptor-affinity comparisons have unknown clinical significance; do not infer equivalent doses to other steroids.
Route-specific PK
Qvar Redihaler active 17-BMP terminal half-life approximately 4 hours, largely esterase metabolism; parent/metabolites mainly fecal elimination, urine<10%. Qnasl intranasal study terminal half-lives approximately 0.3 hours parent and 4.5 hours 17-BMP; relative systemic exposure lower than the studied older orally inhaledQvar MDI, not a Redihaler conversion or universal absolute bioavailability. Both can have systemic steroid effects.
Monitoring and counseling
Check technique, adherence, control and adverse effects.
Monitoring priorities
Qvar: symptoms/rescue use/lung function, thrush, growth, adrenal symptoms during transition/stress, bone risk and visual changes. Qnasl: nasal response/mucosa/bleeding, growth, eye/adrenal effects. Review infection exposures and allergy, demonstrate device use and confirm age/strength. No universal cortisol/lab timetable or specialist dose conversion invented.
Counseling
Use daily as prescribed; Qvar is not acute relief and Qnasl may not immediately relieve rhinitis. Follow asthma rescue/emergency plan, rinse/spit after lung doses, avoid spraying nasal product into mouth/eyes or onto septum. Keep devices clean/dry and discard at counter 0; Qvar at 20 remaining indicates refill reminder. Do not share devices, switch actuators or stop systemic steroids independently; report visual change, persistent nasal lesions, thrush or serious symptoms.
Product identification
Actuator strength and device are part of the prescription.
Representative Qvar Redihaler
- 40 mcg
- Beige actuator/white cap, 120 inhalations, NDC 59310-302-40; 40 mcg mouthpiece vs 50 mcg valve.
- 80 mcg
- Maroon actuator/white cap, 120 inhalations, NDC 59310-304-80; 80 mcg mouthpiece vs 100 mcg valve.
- Device
- Sealed breath-actuated 10.6 g canister with counter; no spacer/priming/shaking. Prescription.
Dosage forms and strengths
- Qnasl 80 mcg
- 10.6 g canister, 120 actuations NDC 59310-410-12; 80 mcg nasal actuator/100 mcg valve.
- Qnasl 40 mcg
- 6.8 g canister, 60 actuations NDC 59310-406-06; 40 mcg nasal actuator/50 mcg valve.
- Excluded formulations
- Older Qvar press-and-breatheMDI, aqueous Beconase-type sprays and international products require current exact-label/device review; no unverified dosing or availability claim.
Storage and handling
Qvar 25°C with 15–30°C excursions (IFU 20–25°C); use at room temperature, cap closed, dry weekly cleaning. Qnasl 20–25°C with 15–30°C excursions; do not remove canister or change actuator, wipe dry after use. Both pressurized: avoid flame/heat and>49°C, no fire/incineration/puncturing. Discard when counter 0; Qvar also by expiration, whichever first. Keep away from children.
References
Original sources for the clinical and product information.
- DailyMed / official U.S. product labelingQvar Redihaler · Teva current full label and IFU
Clinical PI/Patient Information/IFU September 2025; later API September 2026 publication; SPL v 17 effective 20250930; API publication Sep 14, 2026. Clinical revision is distinct from publication. Checked October 1, 2026.
- DailyMed / official U.S. product labelingQnasl · Teva current full label and IFU
Clinical PI/Patient Information February 2020; IFUs March 2018; current SPL API September 2026 publication distinct; SPL v 9 effective 20200229; API publication Sep 28, 2026. Clinical revision is distinct from publication. Checked October 1, 2026.